Passage Bio (PASG)
NASDAQ:PASG
PASG Stock Chart & Stats
$7.10
>-$0.01(-0.86%)
At close: 4:00 PM EST
$7.10
>-$0.01(-0.86%)
Day’s Range― - ―
52-Week Range$5.12 - $20.00
Previous CloseN/A
Volume182.24K
Average Volume (3M)41.18K
Market Cap
$22.10M
Enterprise Value-$191.19K
Total Cash (Recent Filing)$46.30M
Total Debt (Recent Filing)$24.01M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
May 19, 2026EPS Estimate
-2.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.09
Shares Outstanding3,207,810
10 Day Avg. Volume55,130
30 Day Avg. Volume41,182
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.19
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.51
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$25.33Price Target Upside256.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-8.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker EvidenceSustained increases in cerebrospinal fluid progranulin and stabilization of neurofilament light chain in treated patients support the therapy's biological rationale and suggest potential for clinical benefit if safety issues are resolved.
Clinical AdvancementProtocol amendments and active enrollment with initial patients dosed across multiple cohorts indicate the Phase 1/2 program is progressing through clinical stages and continuing planned independent safety reviews.
Valuation UpsideShares trading at a negative enterprise value create a potential upside skew ahead of forthcoming biomarker readouts and regulatory feedback, offering a favorable risk-reward profile for investors who anticipate positive data.
Bears Say
Cash And Financing RiskLimited available cash presents an overhang on the company's ability to fund operations, increasing the likelihood of dilutive financing or delays in development if additional capital is required.
Class Oncogenesis And Durability RiskA reported tumor linked to viral genome integration in a different program and competitor signs of declining biomarker durability raise class-wide concerns that could prompt heightened regulatory scrutiny or additional data requirements.
Safety ConcernsA serious adverse event of pulmonary embolism after a second dose and other safety issues in the lead gene therapy programs have prompted protocol amendments and leave unresolved risk around tolerability.
Passage Bio News
PASG FAQ
What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $5.12 and its highest was $20.00 in the past 12 months.
What is Passage Bio’s market cap?
Passage Bio’s market cap is $22.10M.
When is Passage Bio’s upcoming earnings report date?
Passage Bio’s upcoming earnings report date is May 19, 2026 which is in 53 days.
How were Passage Bio’s earnings last quarter?
Passage Bio released its earnings results on Mar 03, 2026. The company reported -$4.09 earnings per share for the quarter, missing the consensus estimate of -$2.568 by -$1.522.
Is Passage Bio overvalued?
According to Wall Street analysts Passage Bio’s price is currently Undervalued.
Does Passage Bio pay dividends?
Passage Bio does not currently pay dividends.
What is Passage Bio’s EPS estimate?
Passage Bio’s EPS estimate is -2.56.
How many shares outstanding does Passage Bio have?
Passage Bio has 3,207,810 shares outstanding.
What happened to Passage Bio’s price movement after its last earnings report?
Passage Bio reported an EPS of -$4.09 in its last earnings report, missing expectations of -$2.568. Following the earnings report the stock price went down -8.884%.
Which hedge fund is a major shareholder of Passage Bio?
Currently, no hedge funds are holding shares in PASG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Passage Bio
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
PASG Stock 12 Month Forecast
Average Price Target
$25.33
▲(256.76% Upside)
Technical Analysis
Tempest Therapeutics
―
Chemomab Therapeutics
―
Annovis Bio
―
―
Cognition Therapeutics
―
Ownership Overview
Currently, No data available
---